Literature DB >> 1475222

An alternative approach for assessment of rate of absorption in bioequivalence studies.

M L Chen1.   

Abstract

The partial area method was investigated for evaluation of equivalency in the rate of absorption of immediate release formulations. The applicability of the method was demonstrated with four drugs with different pharmacokinetic/pharmacodynamic characteristics. The confidence interval approach currently employed for bioequivalence determinations was applied to the relevant absorption parameters, including Cmax and partial AUCs. The method was found to be more discriminating than Cmax and/or Tmax in the evaluation of the absorption rate of drugs. The cutoff time or point for partial AUC calculation may vary with the type of drug under study, depending on its clinical use and onset of action. The method was shown to be useful in the assessment of rate of absorption in bioequivalence studies.

Mesh:

Substances:

Year:  1992        PMID: 1475222     DOI: 10.1023/a:1015842425553

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  9 in total

1.  Assay of sulfonylureas in human plasma by high-performance liquid chromatography.

Authors:  S Sved; I J McGilveray; N Beaudoin
Journal:  J Pharm Sci       Date:  1976-09       Impact factor: 3.534

2.  Center of gravity of drug level curves: a model-independent parameter useful in bioavailability studies.

Authors:  P Veng-Pedersen; L G Tillman
Journal:  J Pharm Sci       Date:  1989-10       Impact factor: 3.534

3.  Assessment of rate of absorption in bioequivalence studies.

Authors:  L Aarons
Journal:  J Pharm Sci       Date:  1987-10       Impact factor: 3.534

4.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

5.  Generic drugs and the prescribing physician.

Authors:  S L Nightingale; J C Morrison
Journal:  JAMA       Date:  1987-09-04       Impact factor: 56.272

6.  Application of moment analysis in assessing rates of absorption for bioequivalency studies.

Authors:  A J Jackson; M L Chen
Journal:  J Pharm Sci       Date:  1987-01       Impact factor: 3.534

7.  Comparison of statistical moment parameters to Cmax and tmax for detecting differences in in vivo dissolution rates.

Authors:  K C Khoo; M Gibaldi; R K Brazzell
Journal:  J Pharm Sci       Date:  1985-12       Impact factor: 3.534

8.  High-pressure liquid chromatographic determination of ibuprofen in plasma.

Authors:  J L Shimek; N G Rao; S K Khalil
Journal:  J Pharm Sci       Date:  1981-05       Impact factor: 3.534

9.  Trazodone--a new assay procedure and some pharmacokinetic parameters.

Authors:  S I Ankier; B K Martin; M S Rogers; P K Carpenter; C Graham
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

  9 in total
  26 in total

1.  Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence? FDA Biopharmaceutics Coordinating Committee.

Authors:  R L Williams; W Adams; M L Chen; D Hare; A Hussain; L Lesko; R Patnaik; V Shah
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jan-Mar       Impact factor: 2.441

2.  Sensitivity of empirical metrics of rate of absorption in bioequivalence studies.

Authors:  A Ring; L Tothfalusi; L Endrenyi; M Weiss
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

3.  Novel direct curve comparison metrics for bioequivalence.

Authors:  J E Polli; A M McLean
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

Review 4.  Measures of exposure versus measures of rate and extent of absorption.

Authors:  M L Chen; L Lesko; R L Williams
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  An in vitro methodology for forecasting luminal concentrations and precipitation of highly permeable lipophilic weak bases in the fasted upper small intestine.

Authors:  Dimitrios Psachoulias; Maria Vertzoni; James Butler; David Busby; Moira Symillides; Jennifer Dressman; Christos Reppas
Journal:  Pharm Res       Date:  2012-08-14       Impact factor: 4.200

Review 6.  Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi; Alfredo Garcia Arieta
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Use of truncated areas to measure extent of drug absorption in bioequivalence studies: effects of drug absorption rate and elimination rate variability on this metric.

Authors:  J Kharidia; A J Jackson; L A Ouderkirk
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

Review 8.  Bioequivalence assessment of generic drugs: an American point of view.

Authors:  R Patnaik; L J Lesko; K Chan; R L Williams
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

9.  Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets.

Authors:  Laszlo Tothfalusi; Szilvia Speidl; Laszlo Endrenyi
Journal:  Br J Clin Pharmacol       Date:  2007-08-15       Impact factor: 4.335

10.  Metrics comparing simulated early concentration profiles for the determination of bioequivalence.

Authors:  L Endrenyi; F Csizmadia; L Tothfalusi; M L Chen
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.